Could fewer heart scans be safer for breast cancer patients?

NCT ID NCT07630402

Recruiting now Knowledge-focused Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a personalized approach to heart imaging can safely reduce the number of echocardiograms women with early-stage breast cancer need during HER2-targeted therapy. The goal is to avoid unnecessary tests while still catching any heart side effects early. Twenty women will be enrolled, and researchers will track how many imaging tests are done and how long it takes to complete their cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Echocardiogram (ultrasound of the heart)
What this could lead to: If successful, this could lead to a smarter, safer way to monitor heart health during breast cancer treatment, reducing the burden of extra tests.
What could go wrong: This is a very small pilot study (20 participants) with no control group, so results may not apply broadly. The approach may not reliably detect heart problems early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER WITH LOW TO INTERMEDIATE HER2 EXPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER WITH LOW TO INTERMEDIATE HER2 EXPRESSION

Contacts and locations

Locations

Wilmot Cancer Center
RECRUITING

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.